Last reviewed · How we verify
Part B
Part B refers to Medicare Part B, which is a government insurance program, not a pharmaceutical drug.
At a glance
| Generic name | Part B |
|---|---|
| Also known as | MORPHINE GROUP, Rituximab, Ifosfamide, Ifex®, Etoposide |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This appears to be a misidentification. 'Part B' is not a drug name but rather a component of the U.S. Medicare insurance system that covers physician services, outpatient care, and durable medical equipment. There is no marketed pharmaceutical drug by this name from GlaxoSmithKline.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- Phase 2b Controlled Study of Dosing Techniques - Part B (PHASE2)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor (PHASE1, PHASE2)
- Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers (PHASE1)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial (NA)
- Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part B CI brief — competitive landscape report
- Part B updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI